Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy

PLoS ONE

Volumn 3, Issue 6, 2008, Pages

  Dylla, Scott J ^a   Beviglia, Lucia ^a   Park, In Kyung ^a   Chartier, Cecile ^a   Raval, Janak ^a   Ngan, Lucy ^a   Pickell, Kellie ^a   Aguilar, Jorge ^a   Lazetic, Sasha ^a   Smith Berdan, Stephanie ^a   Clarke, Michael F ^b   Hoey, Tim ^a   Lewicki, John ^a   Gurney, Austin L ^a  

^a OncoMed Pharmaceuticals Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; CYCLOPHOSPHAMIDE; IRINOTECAN; LENTIVIRUS VECTOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL CLONE; CELL SELECTION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; PHENOTYPE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ANIMAL; COLORECTAL TUMOR; CYTOLOGY; GENETICS; PATHOLOGY;

MUS;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CYCLOPHOSPHAMIDE; HUMANS; MICE; NEOPLASTIC STEM CELLS;

EID: 49149107236     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002428     Document Type: Article

References (49)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
2. Clarke MF, Fuller M (2006) Stem cells and cancer: two faces of eve. Cell 124: 1111-1115.
3. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, et al. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667.
4. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res 66: 9339-9344.
5. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317: 337.
6. Kennedy JA, Barabe F, Poeppl AG, Wang JC, Dick JE (2007) Comment on "Tumor growth need not be driven by rare cancer stem cells". Science 318: 1722; author reply 1722.
7. Kern SE, Shibata D (2007) The fuzzy math of solid tumor stem cells: a perspective. Cancer Res 67: 8985-8988.
8. Polyak K (2007) Breast cancer stem cells: a case of mistaken identity? Stem Cell Rev 3: 107-109.
9. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
10. Huff CA, Matsui WH, Douglas Smith B, Jones RJ (2006) Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer 42: 1293-1297.
11. Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45: 872-877.
12. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
13. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101: 14228-14233.
14. Staud F, Pavek P (2005) Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37: 720-725.
15. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al. (2008) Identification of cells initiating human melanomas. Nature 451: 345-349.
16. Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827-4833.
17. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, et al. (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219.
18. Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, et al. (2007) Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 67: 398-407.
19. Todaro M, Alea M, Di Stefano A, Cammareri P, Vermeulen L, et al. (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of IL-4. Cell Stem Cell 1: 389-402.
20. Moreb JS, Mohuczy D, Ostmark B, Zucali JR (2007) RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 59: 127-136.
21. Sladek NE, Kollander R, Sreerama L, Kiang DT (2002) Cellular levels of aldehyde debydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 49: 309-321.
22. Boddy AV, Yule SM (2000) Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 38: 291-304.
23. Vasiliou V, Pappa A, Estey T (2004) Role of human aldehyde dehydrogenases in endobiotic arid xenobiotic metabolism. Drug Metab Rev 36: 279-299.
24. Sladek NE (1999) Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des 5: 607-625.
25. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, et al. (2005) Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 37: 611-703.
26. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Del Bo R, et al. (2006) Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1. Hum Mol Genet 15: 167-187.
27. Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, et al. (2004) Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 104: 1648-1655.
28. Fallon P, Gentry T, Balber AE, Boulware D, Janssen WE, et al. (2003) Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engrafment following autologous transplantation. Br J Haematol 122: 99-108.
29. AJ-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
30. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104: 10158-10163.
31. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
32. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
33. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
34. Russo JE (1997) Inhibition of mouse and human class 1 aldehyde dehydrogenase by 4-(N,N-dialkylamino)benzaldehyde compounds. Adv Exp Med Biol 414: 217-224.
35. Russo JE, Hilton J, Colvin OM (1989) The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. Prog Clin Biol Res 290: 65-79.
36. Bettess MD, Dubois N, Murphy MJ, Dubey C, Roger C, et al. (2005) c-Myc is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium. Mol Cell Biol 25: 7868-7878.
37. Malaterre J, Carpinelli M, Ernst M, Alexander W, Cooke M, et al. (2007) c-Myb is required for progenitor cell homeostasis in colonic crypts. Proc Natl Acad Sci U S A 104: 3829-3834.
38. Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, et al. (2006) Rapid loss of intestinal crypts upon conditional deletion of the Wnt/ Tcf-4 target gene c-Myc. Mol Cell Biol 26: 8418-8426.
39. van de Wetering M, Sancho E, Verweij C, de Lan W, Oving I, et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250.
40. Bates RC, Pursell BM, Mercurio AM (2007) Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells. Cells Tissues Organs 185: 29-39.
41. Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981.
42. Mahmoud MI, Potter JJ, Colvin OM, Hilton J, Mezey E (1993) Effect of 4-(diethylamino)benzaldehyde on ethanol metabolism in mice. Alcohol Clin Exp Res 17: 1223-1227.
43. Moreb JS, Gabr A, Vartikar GR, Gowda S, Zucali JR, et al. (2005) Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther 312: 339-345.
44. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G (2004) ALCAM/ CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57: 1160-1164.
45. Thompson MA, Rosenthal MA, Ellis SL, Friend AJ, Zorbas MI, et al. (1998) c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression. Cancer Res 58: 5168-5175.
46. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, et al. (2007) Myc deletion rescues Apc deficiency in the small intestine. Nature 446: 676-679.
47. Tallman MS (2004) Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 41: 27-32.
48. Freemantle SJ, Spinella MJ, Dmitrovsky E (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22: 7305-7315.
49. Nolta JA, Dao MA, Wells S, Smogorzewska EM, Kohn DB (1996) Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc Natl Acad Sci U S A 93: 2414-2419.